Climb Bio Stock Performance
| CLYM Stock | 1.51 0.05 3.42% |
On a scale of 0 to 100, Climb Bio holds a performance score of 7. The firm shows a Beta (market volatility) of 1.55, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Climb Bio will likely underperform. Please check Climb Bio's potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether Climb Bio's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Climb Bio are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Climb Bio displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 05/19/2025 |
2 | Climb Bio Receives Buy Rating from BTIG with 7 Price Target CLYM Stock News | 05/22/2025 |
3 | Insider Trading | 05/23/2025 |
4 | Acquisition by Thomas Stephen Basil of 40000 shares of Climb Bio at 1.29 subject to Rule 16b-3 | 06/04/2025 |
5 | Oppenheimer Initiates Coverage on Climb Bio with Optimistic Outlook CLYM Stock News | 06/06/2025 |
6 | Shares of Tiziana Life Sciences Climb on CEOs Upcoming P - GuruFocus | 06/13/2025 |
7 | Disposition of 5000 shares by Emily Pimblett of Climb Bio subject to Rule 16b-3 | 06/18/2025 |
8 | Disposition of 1242 shares by Emily Pimblett of Climb Bio at 1.24 subject to Rule 16b-3 | 06/20/2025 |
9 | Disposition of 25094 shares by Thomas Stephen Basil of Climb Bio subject to Rule 16b-3 | 06/27/2025 |
10 | Disposition of 20618 shares by Brennan Aoife of Climb Bio at 1.22 subject to Rule 16b-3 | 06/30/2025 |
11 | Acquisition by Emily Pimblett of 100000 shares of Climb Bio at 1.92 subject to Rule 16b-3 | 07/11/2025 |
| Begin Period Cash Flow | 93.1 M | |
| Total Cashflows From Investing Activities | -121.1 M |
Climb Bio Relative Risk vs. Return Landscape
If you would invest 123.00 in Climb Bio on April 21, 2025 and sell it today you would earn a total of 28.00 from holding Climb Bio or generate 22.76% return on investment over 90 days. Climb Bio is currently generating 0.4095% in daily expected returns and assumes 4.1436% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Climb, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Climb Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Climb Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Climb Bio, and traders can use it to determine the average amount a Climb Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0988
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CLYM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.14 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.41 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Climb Bio is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Climb Bio by adding it to a well-diversified portfolio.
Climb Bio Fundamentals Growth
Climb Stock prices reflect investors' perceptions of the future prospects and financial health of Climb Bio, and Climb Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Climb Stock performance.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | (11.77 M) | ||||
| Shares Outstanding | 67.58 M | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (30.36 M) | ||||
| Net Income | (73.9 M) | ||||
| Total Debt | 532 K | ||||
| Book Value Per Share | 2.86 X | ||||
| Cash Flow From Operations | (15.56 M) | ||||
| Earnings Per Share | (1.78) X | ||||
| Market Capitalization | 85.82 M | ||||
| Total Asset | 217.19 M | ||||
| Retained Earnings | (229.88 M) | ||||
| Working Capital | 149.94 M | ||||
About Climb Bio Performance
By examining Climb Bio's fundamental ratios, stakeholders can obtain critical insights into Climb Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Climb Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.35) | (0.37) |
Things to note about Climb Bio performance evaluation
Checking the ongoing alerts about Climb Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Climb Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Climb Bio may become a speculative penny stock | |
| Climb Bio had very high historical volatility over the last 90 days | |
| Climb Bio was previously known as ELYM Old and was traded on NASDAQ Exchange under the symbol ELYM. | |
| Net Loss for the year was (73.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Climb Bio generates negative cash flow from operations | |
| Climb Bio has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Disposition of 20618 shares by Brennan Aoife of Climb Bio at 1.22 subject to Rule 16b-3 |
- Analyzing Climb Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Climb Bio's stock is overvalued or undervalued compared to its peers.
- Examining Climb Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Climb Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Climb Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Climb Bio's stock. These opinions can provide insight into Climb Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.